Introduction

Down’s syndrome (DS) was first described in 1866 by John Langdon Down. It is the most common chromosomal abnormality. The incidence of DS in world literature varies from 1/600 to 800; in Mexico it is reported to be 1/420 to 480. Because of a defect in the distribution of chromosomes in DS affected individuals have three copies of chromosome 21, clinical manifestations are variable and cannot establish the type of chromosomal abnormality, therefore the diagnosis requires a karyotype determination.

The prevalence of congenital heart disease (CHD) in DS is approximately 43%. The most common cardiac malformations associated with DS include atrioventricular canal, patent ductus arteriosus and atrial septal defect (ASD) and ventricular septal defect (VSD). Some of the congenital heart conditions have intra and extra-cardiac shunts that can lead to pulmo-
Pulmonary Hypertension in Down's Syndrome: Nilda Espinola-Zavaleta, et al.

Pulmonary hypertension (PH) due to volume overload of pulmonary circulation and to structural remodeling of pulmonary vasculature. However, PH has also been found in patients with DS without associated CHD. The best non-invasive method to detect CHD and to determine the systolic pulmonary artery pressure (SPAP) at present is echocardiography. Early diagnosis of congenital heart conditions and PH can be crucial for effective treatment that provides optimum quality of life in DS patients. The objectives of our study were to determine the prevalence of CHD and PH by clinical, electrocardiographic and echocardiographic evaluation in the DS at a moderate altitude of Mexico City.

METHODS

All parents and/or guardians of DS subjects signed informed consent for inclusion in the study.

PATIENTS

Between January of 2010 and January of 2013, 127 patients who had no echocardiographic study and accepted to participate were selected, including 64 males (50.4%) and 63 females (49.6%). All had undergone genetic study, were born and lived in Mexico City (altitude: 2240 meters).

Clinical histories were taken on all patients including data of file such as the gyneco-obstetric history of the mother, history of hypothyroidism, mass surface index and complete physical exam.

Prospectively an otorhinolaryngeal examination of the upper airway was performed on all patients aged more than five years (95/127). The criteria used to define upper airway obstruction were: narrowing of nasopharynx and tonsillar, adenoidal and nasal conchæ enlargement.

A twelve lead surface standard electrocardiogram and a transthoracic echocardiogram were performed.

TRANSTHORACIC ECHOCARDIOGRAM

Transthoracic echocardiogram was performed in the supine position, without sedation or supplemental oxygen and with a responsible family member present. The equipment used was a Philips iE33 ultrasound system (Philips Medical Systems, Bothell, WA, USA) with an S5-1 chest wall transducer. Each study included M-mode, two dimensional, pulsed, color and continuous wave Doppler elements. Left ventricular ejection fraction (LVEF) was assessed from an apical 4-chamber image captured by tissue Doppler imaging-echocardiographers. The diagnosis of congenital heart defects was established in the DS patients by clinical, electrocardiographic and echocardiographic evaluation in the DS at a moderate altitude of Mexico City.

The Qp/Qs was calculated using a previously described formula. The mean pressure of the pulmonary artery (MPAP) was calculated with the following formula: $0.61 \times SPAP + 2 \text{ mm Hg}$ and was considered normal when it was $\leq 25 \text{ mm Hg}$.

Statistical analysis

Numeric variables were evaluated with a Gaussian distribution. The mean and standard deviation and in categorical variables with percentages. Bivariate analysis was adjusted according to the distribution. Student’s $t$ or the Mann-Whitney $U$ tests were used with categorical variables as well as $\chi^2$ with Yates’ correction or the Fisher exact test. The 95% confidence interval (CI 95%) was calculated for the difference of proportions and the statistical power of a bilateral test to compare two proportions in a transverse study, prevalence of PH and CHD, prevalence ratios with CI 95%, and odds ratio with CI 95% for PH and for each of the variables found to be significant.

RESULTS

Mean ages of the patients, mothers and fathers and the relaxation time $\geq 220$ msec. Type I diastolic dysfunction was identified when the E/A ratio was $\leq 0.99$. Type II was associated with a pseudo-normal E/A ratio (1.0–1.49) with a deceleration time $< 160$ msec and an E/A ratio of $\geq 1.5$ defined type III diastolic dysfunction. The right ventricular diastolic diameter was measured from an apical 4-chamber image at a level above the tricuspid valve. A normal value was considered to be $\leq 40$ mm. Right ventricular systolic function was evaluated on the basis of tricuspid annular peak systolic excursion (TAPSE) measured from M-mode tracing taken from an apical 4-chamber view with $\geq 16$ mm as normal. The peak velocity of the tricuspid ring was measured using the $S$ wave velocity from the apical 4-chamber image captured by tissue Doppler (normal value was considered to be $\geq 10.5$ cm/sec). Tricuspid regurgitation peak velocity was used to determine SPAP. This was done calculating the systolic tricuspid gradient using the modified Bernoulli equation, and then adding an assumed or calculated right atrial pressure. The final value of the SPAP was the average of three consecutive determinations. In cases with VSD or patent ductus arteriosus the SPAP was estimated as the systemic systolic arterial pressure minus the gradient of the shunt. Systolic PH was classified as 1) mild: 30–40 mm Hg, 2) moderate: 50–69 mm Hg, and 3) severe $\geq 70$ mm Hg. This classification of PH was based on a consensus of experts from the American College of Cardiology Foundation/American Heart Association 2009 meeting. The mean pressure of the pulmonary artery (MPAP) was calculated with the following formula: $0.61 \times SPAP + 2 \text{ mm Hg}$ and was considered normal when it was $\leq 25 \text{ mm Hg}$.

The right ventricular diastolic diameter was measured from an apical 4-chamber image at a level above the tricuspid valve. A normal value was considered to be $\leq 40$ mm. Right ventricular systolic function was evaluated on the basis of tricuspid annular peak systolic excursion (TAPSE) measured from M-mode tracing taken from an apical 4-chamber view with $\geq 16$ mm as normal. The peak velocity of the tricuspid ring was measured using the $S$ wave velocity from the apical 4-chamber image captured by tissue Doppler (normal value was considered to be $\geq 10.5$ cm/sec). Tricuspid regurgitation peak velocity was used to determine SPAP. This was done calculating the systolic tricuspid gradient using the modified Bernoulli equation, and then adding an assumed or calculated right atrial pressure. The final value of the SPAP was the average of three consecutive determinations. In cases with VSD or patent ductus arteriosus the SPAP was estimated as the systemic systolic arterial pressure minus the gradient of the shunt. Systolic PH was classified as 1) mild: 30–40 mm Hg, 2) moderate: 50–69 mm Hg, and 3) severe $\geq 70$ mm Hg. This classification of PH was based on a consensus of experts from the American College of Cardiology Foundation/American Heart Association 2009 meeting. The mean pressure of the pulmonary artery (MPAP) was calculated with the following formula: $0.61 \times SPAP + 2 \text{ mm Hg}$ and was considered normal when it was $\leq 25 \text{ mm Hg}$.

The diagnosis of congenital heart defects was established in the following sequence: situs, atrioventricular and ventriculoarterial concordance, associated defects (ASD and VSD and patent ductus arteriosus) and valve lesions (stenosis and/or regurgitation). The Qp/Qs was calculated using a previously described formula. All studies were performed by cardiologist-echocardiographers.
number of maternal pregnancies are described in Table 1. DS was the result of trisomy 21 in 97% of the subjects and translocation in 3%. Five patients (4%) reported faintness, 3 (2.4%) chest pain and 2 (1.6%) occasional palpitations. In 82% the cardiovascular examination was normal. In the remaining subjects, acrocyanosis and clubbed fingers were found. Of the subjects more than 5 years of age, 86% (82/95) had obstruction of the upper airway caused by tonsillar enlargement (70%, 67/95) or enlargement of tonsils and nasal conchae (16%, 15/95).

According to the clinical evaluation, 81.1% (103/127), were in the New York Heart Association functional class I, 17.3% were in class II and 1.6% in class III (Table 1).

**Therapy**

89.8% (114/127) received no medical treatment (Table 1). Angiotensin converting enzyme inhibitors, loop diuretics or spironolactone were prescribed in 11.2% (13/127). None received permanent oxygen (≥ 18 hours). Eight (6.3%) were hypothyroid and were treated with levothyroxine.

The electrocardiogram was normal in 46% (58/127). Right bundle branch block and enlarged right heart were present in the majority of the remaining patients (Table 2).

**Table 1. Demographic findings (n = 127)**

| Variable                        | Patients | Mothers | Fathers |
|---------------------------------|----------|---------|---------|
| Age (years ± SD)                | 16.4 ± 12| 32.1 ± 6.8| 35.7 ± 8.0|
| Number of maternal pregnancies  | 2 (1–9)  | 44.4 ± 20.0| 1.3 ± 0.2|
| Body surface index (m²)         | 23.0 ± 7.1| 44.4 ± 20.0| 1.3 ± 0.2|
| NYHA class                      |          |         |         |
| I                               | 103.0 (81.1%)| 44.4 ± 20.0| 13.0 (11.2%)|
| II                              | 22.0 (17.3%)| 0         | 15.0 (16%)|
| III                             | 2.0 (1.6%)| 0         | 13.0 (14%)|
| Without medications             | 114.0 (89%)| 0         | 15.0 (16%)|
| With medications                | 13.0 (11.2%)| 0         | 15.0 (16%)|
| ENT evaluation (95/127)         |          |         |         |
| Tonsillar enlargement           | 67.0 (70%)| 0         | 15.0 (16%)|
| Enlargement of tonsils and nasal conchae | 15.0 (16%)| 0         | 13.0 (14%)|
| Patent upper airway             | 13.0 (14%)| 0         | 15.0 (16%)|

SD: standard deviation, NYHA: New York Heart Association, ENT: ear nose and throat, kg: kilograms, m: meters, m²: square meters

**Table 2. Electrocardiographic findings (n = 127)**

| Variable                  | n (%) |
|---------------------------|-------|
| Normal                    | 58 (46)|
| RBBB                      | 43 (34)|
| RBBB and DRV              | 10 (8) |
| DRV                       | 13 (10)|
| DRV and DLV               | 3 (2)  |

RBBB: right bundle branch block, DRV: dilated right ventricle, DLV: dilated left ventricle

**Table 3. Echocardiographic findings (n = 127)**

| Variable                  | Without congenital heart defect | With congenital heart defect | P |
|---------------------------|---------------------------------|-----------------------------|---|
| Aortic diameter (mm)      | 26.0 ± 7.7                      | 34.4 ± 9.6                  | 0.001|
| Left atrial diameter (mm) | 28.0 ± 5.0                      | 34.0 ± 8.0                  | NS |
| Left ventricular ejection fraction (%) | 67.0 ± 6.0 | 65.0 ± 6.0 | NS |
| E/A ratio                 | 1.6 ± 0.5                       | 1.6 ± 0.5                   | NS |
| LVDD (mm)                 | 35.8 ± 12.0                     | 36.0 ± 7.0                  | NS |
| TAPSE (mm)                | 20.0 ± 4.0                      | 19.0 ± 4.0                  | NS |
| S wave velocity (cm/sec)  | 7.5 ± 2.9                       | 7.3 ± 3.6                   | NS |
| SPAP (mm Hg)              | 37.2 ± 12.0                     | 50.5 ± 15.0                 | 0.001 |
| MPAP (mm Hg)              | 26.0 ± 6.0                      | 34.4 ± 16.0                 | 0.001 |

Values are expressed as mean ± standard deviation. LVDD: left ventricular diastolic diameter, TAPSE: tricuspid annular peak systolic excursion, SPAP: systolic pulmonary artery pressure, MPAP: mean pulmonary artery pressure, S: systolic, NS: not significant

**Fig. 1.** Anatomoechoardiographic correlation of an isolated cleft of the septal leaflet of the mitral valve: A: Echocardiographic image showing the cleft of the septal mitral leaflet with a white arrow. B: Internal view of anatomic specimen showing left cardiac cavities, the black arrow points the cleft of the septal mitral leaflet. LA: left atrium, LV: left ventricle, RA: right atrium, RV: right ventricle.
ECHOCARDIOGRAPHIC FINDINGS (Table 3)

LVEF and TAPSE were normal in all subjects. The S wave velocity was abnormal (7.5 ± 3.2 cm/sec) in 84% (107/127). Left ventricular diastolic function was abnormal in 68% (86/127). Twelve (9.5%) had type I dysfunction, 17 (13.5%) type II and 57 (45%) type III.

Associated CHD was found in 40% (51/127). Patent ductus arteriosus, ASD and isolated cleft of the anterior mitral leaflet (Fig. 1) were the most frequent. The VSD was perimembranous in all, and in 3 the VSD reached the left ventricular inlet (Table 4). The Qp/Qs was 2.0 ± 0.7.

The SPAP and the MPAP for the group were 42.5 ± 17 mm Hg and 29 ± 11 mm Hg, respectively. Subjects without associated CHD (76/127) had a SPAP and a MPAP of 36.5 ± 8.9 mm Hg and 25.3 ± 5.6 mm Hg, respectively. In those cases with CHD the SPAP was 48 ± 20 mm Hg and the MPAP 33 ± 12 mm Hg (p < 0.001).

One hundred two subjects (80%) had PH with a SPAP of 47 ± 19 mm Hg and MPAP of 32 ± 11 mm Hg. When no CHD (58/102) the SPAP was 40 ± 7 mm Hg and the MPAP was 28 ± 4.6 mm Hg. In patients with CHD (44/102) the PASP and MPAP were 51 ± 19 mm Hg and 35 ± 12 mm Hg, respectively (p < 0.001). For patients with DS, CHD, and PH (44/102), we classified them into two groups: 1) those without shunts (18/44), in whom the SPAP was 37 ± 9 mm Hg and the MPAP 25 ± 6 mm Hg, and 2) those with shunts (26/44), in whom the SPAP and the MPAP were 57 ± 29 mm Hg and 38 ± 19 mm Hg, respectively (p < 0.001) (Fig. 2). In the miscellaneous group, which included seventy-six patients that did not have CHD (n = 58) or had heart defects without shunts (n = 18) the SPAP was 37 ± 19 mm Hg and the MPAP 25 ± 6 mm Hg, respectively.

The prevalence of PH in DS was 5.9% at one year and 15% at 10 years. The odds ratio (OR) of PH in DS with CHD was 7.3 vs. 3 without CHD. In subjects with DS and CHD, the probability of developing PH was 46%, while in those with-
our CHD it was 53%. The OR of PH prevalence in DS and CHD was 1.88 (CI 95% 1.02–2.1, \( p \leq 0.001 \)) and the OR of PH prevalence in DS without CHD was 0.50 (CI 95% 0.46–0.70, \( p \leq 0.02 \)) and the OR of PH prevalence in generally in DS was 1.96 (CI 95% 1.1–1.98, \( p \leq 0.0001 \)).

After three years of follow-up one patient had died as a result of PH and right heart failure.

**DISCUSSION**

While DS can be associated with a number of other pathological entities, CHD is the principal cause of increased morbidity and mortality. From 19 to 43% of patients with DS have some type of congenital heart defect.\(^6\) In our study we found that 40% of the subjects had associated CHD, which is consistent with the values reported in the literature.\(^5,9\) In contrast to other reports from Latin America in which ASD was the heart defect most commonly found (24%),\(^9\) in our study patent ductus arteriosus was the abnormality of highest prevalence (22%), probably related with the moderate altitude of Mexico City,\(^20\) with ASD in second place (18%), VSD (14%) in third and atrioventricular septal defect (12%) in fourth place (Fig. 3). In Europe and countries of Anglo-Saxon origin atrioventricular septal defect is the congenital malformation of the heart most commonly associated with DS and varies from 40–80%.\(^9\) In our series 10% of the subjects had multiple heart defects, a much lower percentage than the reported by Frid et al.\(^6\) (30%).

Patients with DS have a much higher risk of developing PH than in the general population.\(^20\) In our series 80% had PH, and it was of greater degree in those with CHD and shunt when compared with patients with DS without CHD, and patients with CHD and without shunts. In the literature it is reported that 90% of patients with DS and CHD develop PH.\(^20\) In this study the prevalence of PH was 5.9% per year with the probability of its development 2.4 times greater in patients with DS and CHD than in those without CHD. Weijerman et al.\(^9\) and Cua et al.\(^20\) found that the prevalence of PH in neonates with DS was 1.2 to 5.2%, while the prevalence in the general population is 0.1%.

In our series, the systolic function of the two ventricles assessed by LVEF and systolic displacement of the tricuspid ring was normal in all DS patients. However, the fact that S wave velocity was decreased may suggest perhaps subclinical right ventricular contractile dysfunction.\(^11,13\) The left ventricular diastolic dysfunction found in 68% of our patients, needs further investigation.

In 1958, Heath and Edwards\(^25\) described the pathological changes of pulmonary vasculature found in patients with intra and extra-cardiac shunts PH. At the altitude of Mexico City (2240 meters) De Micheli et al.\(^20\) reported histological alterations of the media of the pulmonary arteries with moderate PH and of both the media and intima with severe PH. It is noteworthy that patients with DS develop PH even in the absence of congenital heart defects, as we found in 46% of the patients. However, when DS patients were grouped with those with CHD without shunts, the prevalence of PH was higher (76/127 = 59%). In this group some authors have demonstrated pulmonary hypoplasia to be the main cause of PH.\(^20,22\) Obstruction of the upper airway is commonly associated with DS and may contribute to obstructive sleep apnea and chronic hypoxemia, eventually leading to pulmonary vascular disease.\(^25\) In our series 86% of the patients had upper airway obstruction, a similar figure rate to what is reported in the literature.\(^20,22\) It is noteworthy that our patients were evaluated at moderately high altitude where the lower partial pressure of inhaled oxygen could lead to a higher incidence of PH. However, this was not corroborated for DS nor previously in obese or in chronic obstructive pulmonary disease patients.\(^20,22\)

Clinical and electrocardiographic signs of PH were uncommon and consequently these diagnostic modalities rarely corroborated it. Our study demonstrated that the echocardiogram is an indispensable tool in the detection of CHD, diagnosis of PH and its hemodynamic repercussions on the right heart.

**CONCLUSION**

DS has a high prevalence of CHD and PH when compared to the general population. The risk of PH increases 2.4 times when congenital heart defects are present, but it does not seem to be affected by moderate altitude. The etiopathogenesis of PH in patients with DS without CHD remains to be clarified. Its mechanisms will be the focus of investigation in the near future. Echocardiography should be considered to be an indispensable non-invasive tool for the integral evaluation of DS.

**REFERENCES**

1. Martínez-Quintana E, Rodríguez-González F, Medrano-Gil JM, Agredo-Muñoz J, Nieto-Lago V. Clinical outcome in Down syndrome patients with congenital heart disease. Crit Care 2010;78:245-50.
2. Baird PA, Sadovnick AD. Life tables for Down syndrome. Hum Genet 1989;82:291-2.
3. Rodríguez-Hernández L, Reyes-Núñez J. (Congenital cardiopathies in Down’s syndrome). Bol Med Hosp Infant Mex 1984:41:622-5.
4. de Rubens Figueroa J, del Pozo Magaña B, Pablos Hach JL, Calderón Jiménez C, Castrejón Urbina R. (Heart malformations in children with Down syndrome). Rev Esp Cardiol 2003;56:894-9.
5. Weijerman ME, van Furth AM, van der Mooren MD, van Weissenbruch MM, Rammeloo L, Broers CJ, Germke RJ. Prevalence of congenital heart defects and persistent pulmonary hypertension of the neonate with Down syndrome. Eur J Pediatr 2010;169:1193-9.
6. Frid C, Droot P, Lundell B, Rasmussen F, Annerén G. Mortality in Down’s syndrome in relation to congenital malformations. J Intellect Disabil Res 1999;43(3Pt 3):254-41.
7. D’Alto M, Mahadevan VS. Pulmonary arterial hypertension associated with congenital heart disease. Eur Respir J 2012;40:278-37.
8. Suzuki K, Yamaki S, Mimori S, Murakami Y, Mori K, Takahashi Y, Kikuchi T. Pulmonary vascular disease in Down’s syndrome with complete atrioventricular septal defect. Am J Cardiol 2000;86:434-7.
9. Byard RW. Forensic issues in Down syndrome fatalities. J Forensic Leg Med
17. Cherna D, Castelain V, Provencer S, Humbert M, Simonneau G, Herve P. Evaluation of various empirical formulas for estimating mean pulmonary artery pressure by using systolic pulmonary artery pressure in adults. Chest 2009;135:760-8.

18. Tynan MJ, Becker AE, Macartney FJ, Jiménez MQ, Shinebourne EA, Anderson RH. Nomenclature and classification of congenital heart disease. Br Heart J 1979;41:544-53.

19. Kitabatake A, Inoue M, Asao M, Ito H, Masuyama T, Tanouchi J, Morita T, Hori M, Yoshima H, Ohmishi K, et al. Nontimase evaluation of the ratio of pulmonary to systemic flow in atrial septal defect by duplex Doppler echocardiography. Circulation 1984;69:73-9.

20. Mikkelsen M, Poulsen H, Nielsen KG. Incidence, survival, and mortality in Down syndrome in Denmark. Am J Med Genet Suppl 1990;7:75-8.

21. Alzamora-Castro V, Battrilana G, Abugattas R, Sailer S. Patent ductus arteriosus and high altitude. Am J Cardiol 1960;5:761-3.

22. King P, Tulloeh R. Management of pulmonary hypertension and Down syndrome. Int J Clin Pract Suppl 2011;174:8-13.

23. Cua CL, Blankenship A, North AL, Hayes J, Nelin LD. Increased incidence of idiopathic persistent pulmonary hypertension in Down syndrome neonates. Pediatr Cardiol 2007;28:250-6.

24. Lorch SM, Shawkey A. Myocardial velocity, strain, and strain rate abnormalities in healthy obese children. J Cardiometab Syndr 2007;2:30-4.

25. Heath D, Edwards JE. The pathology of hypertensive pulmonary vascular disease; a description of six grades of structural changes in the pulmonary arteries with special reference to congenital cardiac septal defects. Circulation 1958;18(4 Part 1):533-47.

26. De Micheli A, Piccolo E, Espino VeA J, Monroy G, Alvarez VR. Observations on the mechanisms regulating pulmonary pressures in congenital heart diseases with arteriovenous shunt]. Arch Inst Cardiol Mex 1960;30:527-55.

27. Cua CL, Blankenship A, North AL, Hayes J, Nelin LD. Increased incidence of idiopathic persistent pulmonary hypertension in Down syndrome neonates. Pediatr Cardiol 2007;28:250-6.

28. Banjar HH. Down’s syndrome and pulmonary arterial hypertension. PVRI Rev 2009;1:213-6.

29. Lupi-Herrera E, Soeane M, Sandoval J, Casanova JM, Bialostokzy D. Behavior of the pulmonary circulation in the grossly obese patient. Pathogenesis of pulmonary arterial hypertension at an attitude of 2,240 meters. Circulation 1980;70:553-8.

30. Lupi-Herrera E, Sandoval J, Soeane M, Bialostokzy D. Behavior of the pulmonary circulation in chronic obstructive pulmonary disease. Pathogenesis of pulmonary arterial hypertension at an attitude of 2,240 meters. Am Rev Respir Dis 1982;126:509-14.